QuantHealth

**Product and the concrete problem it solves.** QuantHealth addresses the high-cost, high-failure decision point between a promising therapy and a clinical trial. A conventional development team often makes protocol, indication, cohort, endpoint, enrollment, and investment decisions using historical summaries, expert judgment, and successive real-world experiments. Those choices become expensive to change once patients are enrolled. QuantHealth offers a simulation-first workflow in which a biopharma or biotech team can vary trial assumptions and inspect predicted efficacy, safety, feasibility, recruitment, cost, and commercial outcomes before the first patient is recruited. Its platform is not presented as a replacement for a regulated human trial. Rather, it is a pre-trial decision layer intended to identify weak designs, compare alternatives, and help teams decide which questions deserve the cost and ethical burden of prospective testing. The practical value is concentrated in avoiding late discovery of an underpowered cohort, an impractical protocol, a poor indication, or an enrollment plan that cannot meet its timeline.

**Core technology and how it actually works.** QuantHealth describes its system as an AI-powered, patient-centric clinical-trial simulator. The company models diverse virtual patients with individual response profiles and exposes those simulated patients to candidate therapies and trial protocols. Its public materials describe more than 10,000 data points per patient, more than 100,000 drug and mechanism data points, and a training and evidence base that has included real-world patient data, therapeutics, molecules, and historical trials. The platform allows users to alter treatment arms, comparators, endpoints, inclusion and exclusion criteria, analysis methods, and other protocol parameters, then run many counterfactual scenarios. Its indication-selection module compares predicted efficacy and safety across diseases and cohorts; its enrollment module estimates site-level and global recruitment using protocol complexity, site burden, site performance, investigator factors, and cohort definitions; and its probability-of-technical-success workflow combines efficacy and safety simulation with real-world evidence. The company does not publicly disclose a complete model architecture, source-data licensing map, uncertainty-calibration method, or regulator-accepted validation protocol. Its “up to 90%” endpoint-prediction accuracy and 600-plus simulated trials are therefore important company-reported signals, not a blanket guarantee for every disease, endpoint, or sponsor.

**Market, customers, and go-to-market.** The initial market is the global biopharmaceutical development workflow: pharmaceutical companies, biotechnology companies, clinical-development teams, clinical-trial sponsors, portfolio managers, and organizations evaluating licensing or investment decisions. QuantHealth can sell into protocol design, indication selection, enrollment planning, asset evaluation, and market positioning, which creates more than one budget owner and a natural expansion path after an initial simulation project. The company’s public case material includes evidence that it has worked with large pharmaceutical organizations and biotech startups, while its site displays Sanofi and Accenture Ventures endorsements and describes a strategic relationship with Sanofi. QuantHealth has also described a collaboration with a leading contract research organization, and Frost & Sullivan’s award write-up references industry recognition and partnerships including IQVIA. These references establish market access and external interest, but the public record does not disclose a complete customer list, contract sizes, renewal rates, or the share of revenue from recurring software versus services. Its expansion from Israel and Europe into the United States, reported in 2024, is strategically important because U.S. biopharma budgets and clinical-trial decision cycles are much larger, though commercialization there brings demanding validation, privacy, and procurement requirements.

**Traction, funding, and third-party validation.** QuantHealth emerged from stealth in 2022 with a $2.6 million seed round led by Shoni Top and participation from Pitango HealthTech, Nina Capital, Bessemer’s Renegade vehicle, Atooro Fund, Boston Millennia Partners, and Brigham Hyde. It then announced a $15 million Series A in 2023, and independent coverage in 2024 reported that the company had crossed $1 million in annual recurring revenue in 2023 and had completed dozens of simulations for biopharma customers. In October 2025, Sanofi Ventures announced a strategic investment and described total funding of $30 million at that point. On August 4, 2026, QuantHealth raised a $45 million Series B led by Qumra Capital, with participation reported from Artofin, Bertelsmann Healthcare Investments, Esplanade Ventures, GC Ventures, NewHealth Ventures, Pitango HealthTech, Sanofi Ventures, and Shoni Health Ventures. The Israel Innovation Authority profile lists the company as established in 2020, with 85 employees and initial revenues. QuantHealth’s own platform pages cite more than 600 simulated trials across more than 30 indications and prospective examples comparing simulated and actual phase III outcomes. The evidence is meaningful for a mid-stage health-tech company, but public sources still do not provide audited revenue, customer concentration, peer-reviewed validation of the commercial product, regulatory qualification, or proof that simulated accuracy translates into improved phase III approval rates.

**Founders and team background.** QuantHealth was founded by Orr Inbar and Arnon Horev. The Israel Innovation Authority identifies Inbar as CEO and co-founder, while the company identifies Horev as co-founder and Chief Strategy and Operations Officer. Investor interviews describe Inbar as a technology and data-science leader who co-founded ConcertAI and led AI teams in medical companies in Israel and the United States. Horev is described as bringing a business and digital-health background, complementing Inbar’s technical and healthcare-data experience. The current executive group listed by QuantHealth includes Adam Goldberger as CFO, Francisco Beca as Chief Medical Officer, and Nadav Weinberg as SVP Sales. QuantHealth says its team spans AI, data science, biology, medicine, bioinformatics, mathematics, software engineering, product, immunology, pharmacology, and epidemiology; it reports that 36% of staff hold PhDs or MDs and 75% hold advanced degrees. The government profile’s 85-employee figure and the company’s multidisciplinary description suggest real organizational depth for a simulation vendor, while the absence of a published full technical roster makes it difficult to distinguish core proprietary research capacity from implementation and commercial functions. The founder-market fit is strongest in clinical-data interpretation and healthcare commercialization; the key open question is whether the organization has enough statistical, regulatory, and therapeutic-area depth to support high-stakes claims across many indications.

**Competitive dynamics.** QuantHealth competes against several different approaches rather than one direct substitute. Unlearn.AI develops AI-generated digital twins and synthetic control arms for clinical research, which overlaps with QuantHealth’s virtual-patient and counterfactual-trial positioning. Aetion provides real-world evidence analytics and regulatory-oriented causal evidence, competing for the same evidence and development-planning budgets even where its workflow is less prospective. Phesi offers clinical-development intelligence, patient recruitment, and trial-optimization tools, while Medidata combines an installed base in clinical-trial operations with analytics and data products. IQVIA is a particularly formidable incumbent because its CRO, data, technology, and sponsor relationships allow it to bundle trial design and evidence services. Owkin competes in AI-enabled biomarker discovery and clinical research, especially where sponsors want disease-specific predictive models. QuantHealth’s claimed edge is the combination of patient-level simulation, broad protocol parameterization, prospective comparison of predicted and actual outcomes, and an enterprise workflow that reaches from scientific design into enrollment and portfolio decisions. Its most important strategic risk is that a large CRO or data platform can package “good enough” simulation into an existing service relationship, while a specialist such as Unlearn can win credibility in the narrow digital-twin use case. Durable differentiation will require reproducible validation, proprietary data advantages, workflow lock-in, and evidence that simulation changes decisions rather than merely producing attractive scenario dashboards.

**Defense, security, and resilience dual-use relevance.** QuantHealth is not a defense contractor and its public customer evidence is commercial biopharma-oriented. Its dual-use case is instead a health-resilience and medical-countermeasure adjacency. The same ability to simulate patient responses, treatment arms, safety outcomes, cohort composition, and recruitment constraints can support faster development of vaccines, antivirals, oncology treatments, or other therapies needed during outbreaks, mass-casualty events, or supply-constrained public-health emergencies. Defense medical organizations and governments could plausibly use such a platform to prioritize candidate countermeasures, stress-test trial designs for hard-to-recruit populations, and model treatment strategies when prospective data are scarce. A simulation layer can also reduce scarce-patient and scarce-clinician burden by identifying weak hypotheses before they consume clinical capacity. That transfer path is technically credible because it uses the same core engine rather than requiring a separate weapons or surveillance product. The calibration is essential: no reviewed source documents a military customer, government medical-countermeasure program, classified deployment, emergency-use authorization, or operational defense contract. QuantHealth’s strategic relevance should therefore be scored as resilience infrastructure for biomedical R&D, not as fielded defense technology. Diligence should test deployment in sovereign or restricted environments, data residency, privacy-preserving learning, model behavior under sparse or biased data, auditability of recommendations, and whether public-health or defense sponsors can rely on outputs without confusing simulation with clinical evidence.

**Growth stage, trajectory, and key diligence risks.** QuantHealth is classified as mid-stage: it was founded in 2020, has progressed from seed through Series A to a $45 million Series B, reports 85 employees in the Israel Innovation Authority profile, and has public evidence of commercial simulations, strategic investment from Sanofi Ventures, and a growing product surface. Its trajectory is toward becoming a decision infrastructure layer for simulation-first clinical development rather than a single-purpose protocol tool. The upside is substantial if sponsors routinely use virtual cohorts and counterfactual experiments to allocate clinical capital, improve recruitment, and select better drug-indication combinations. The main diligence risks are: (1) **validation risk**, because company-reported accuracy and simulated-trial counts do not equal regulator-accepted evidence; (2) **data and bias risk**, because historical clinical and real-world data can underrepresent populations and encode site or treatment-selection artifacts; (3) **workflow risk**, because sponsors may buy simulations for exploratory work without changing expensive trial decisions; (4) **competition risk**, because CROs, data incumbents, and digital-twin specialists can bundle overlapping capabilities; (5) **regulatory and liability risk**, because a misleading prediction could affect patient exposure, capital allocation, or trial feasibility; (6) **commercial concentration risk**, because public customer names and revenue mix are limited; and (7) **scaling risk**, because supporting many indications requires medical, statistical, engineering, and regulatory expertise simultaneously. The milestones that would increase confidence are peer-reviewed or sponsor-verified prospective validation, repeatable evidence of improved trial success or enrollment, disclosed retention and expansion metrics, regulator engagement, broader sovereign-health deployments, and a clear proprietary-data or model moat.